2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Biological Therapies, Transfusion, Non-Biological Therapies, Devices, Pharmacology, Women’s Health, Adverse Events, Artificial Intelligence (AI), Computer Vision, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Thalassemia, Infectious Diseases, Viral, Bacterial, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Study Population, Human, Adult, Embryo/Fetus, Pediatric, Pregnant, Young Adult
PAPER

1166 Clinical and laboratory findings in adults with sickle cell disease which increase risk for severe acute kidney injury

Jessica Moore, MD, Cassandra Chua, MD2, Bharath Miriyam, MB,BS, MPH3, Nduku Ngomba4, Jason Lofters, MB,BS5, Elizabeth Klings, MD6
1 Boston University Medical Center, Boston, Massachusetts, United States
2 Boston University Medical Center, Boston, Massachusetts, United States
3 Boston University Medical Center, Boston, Massachusetts, United States
4 Boston University Medical Center, Boston, Massachusetts, United States
5 Boston University Medical Center, Boston, Massachusetts, United States, Boston University Medical Center, Boston, Massachusetts, United States
6 Boston University Medical Center, Boston, Massachusetts, United States
Introduction
Acute kidney injury (AKI) is a common, under-recognized complication of sickle cell disease (SCD), driven by vaso-occlusion, hemolysis-mediated renal ischemia, and nephrotoxic medication exposures. In patients with SCD, AKI is associated with prolonged hospitalization, progression to chronic kidney disease, and increased mortality. The SCD Outcomes Grading System (SCOGS) was developed following a three round Delphi consensus methodology including 29 SCD and 18 experts, standardizing classification and grading of 53 SCD complications. AKI severity is graded 1-5 based on the rise in serum creatinine (sCr) relative to baseline and need for renal replacement therapy (RRT): 1) sCr 1.5-1.9x baseline; 2) sCr 2.0-2.9x baseline; 3) sCr ≥3.0x baseline, sCr >4 mg/dL, or RRT initiation without progression to permanent end-stage renal disease (ESRD); 4) Grade 3 plus progression to permanent ESRD; 5) death from AKI. Our study aimed to determine clinical and laboratory factors associated with AKI occurrence and severity in hospitalized adults with SCD.

Methods
Adult patients with SCD hospitalized at a single institution between January 1, 2021 and March 30, 2026 were identified from a clinical data warehouse using ICD-10 billing codes. AKI was defined as a rise in sCr from baseline. Data collected included demographics, clinical history, medication usage, vital signs, laboratory and radiologic data, and treatments received. AKI cases were grouped by severity into mild (Grade 1-2), moderate (Grade 3), and severe (Grade 4-5). Descriptive statistics (mean, SD) were calculated; Kruskal-Wallis testing compared non-normally distributed continuous variables, and Chi-square/Fisher's exact tests compared categorical variables. Univariate and Firth penalized multivariable logistic regression identified predictors of AKI. Data were analyzed using SAS 9.4; significance was defined as p<0.05.

Results
126 hospitalizations were included. The cohort was 60.3% female, and 74.6% had HbSS disease; mean age was 38.8 years (SD±8.7). AKI occurred in 65 (51.6%) admissions. Compared to those without AKI, patients with AKI were older (41.5 vs 36.0 years, p=0.0002), more often female (73.8% vs 45.9%, p=0.0014), and had higher baseline sCr (0.89 vs 0.70 mg/dL, p<0.0001); Hb genotype did not differ significantly. Among the 65 AKI cases, 52 (80.0%) were mild, 10 (15.4%) moderate, and 3 (4.6%) severe. There were no Grade 5 (fatal) events and no patient required RRT. Of admissions with AKI, 42.6% (26/61) had a history of hypertension, 41.0% (25/61) were prescribed outpatient RAAS inhibitors, 25.0% (15/60) were on chronic nonsteroidal anti-inflammatory drug (NSAID) and 39.3% (24/61) received acute NSAIDs during hospitalization. C-reactive protein (CRP) differed significantly across AKI severity grades, highest in Grade 2 (105.7 mg/L) versus Grade 1 (22.4 mg/L), Grade 3 (58.0 mg/L), and Grade 4 (119.2 mg/L) (p=0.0108). Prior acute chest syndrome (ACS) frequency also differed significantly across grades (p=0.04). No significant differences across grades were seen in sex, race, genotype, hemoglobin concentration, WBC/platelet counts, oxygen saturation, transaminases, or bilirubin. On univariate regression adjusted for age and sex, elevated baseline sCr was strongly associated with AKI (OR 331.9, 95% CI 12.9->999.9, p=0.0005), and female sex was independently associated with AKI (OR 3.37, 95% CI 1.23-9.26, p=0.02). Prior ACS was associated with AKI when adjusted for age (OR 14.17, 95% CI 1.34- 149.76, p=0.03). A Firth penalized multivariable model (temperature, CRP, exchange transfusion, prior ACS, age, sex, hydroxyurea, hemoglobin, WBC) demonstrated good discrimination (cstatistic 0.85), though no individual predictor reached significance (p=0.08).

Conclusion
Adult patients with SCD experience a spectrum of AKI severity, occurring in over half of hospitalizations reviewed, most of which were mild. Using the SCOGS severity scale, higher AKI severity was associated with elevated CRP and prior ACS history, while elevated baseline sCr and female sex were the strongest independent predictors of AKI overall. These findings need prospective confirmation in a larger cohort, but suggest that clinical and laboratory data at presentation may help identify SCD patients at increased AKI risk, informing earlier nephroprotective strategies and closer renal monitoring.
Jessica Moore, MD: No relevant conflicts of interest to declare.